Börse:

Agios Pharmaceuticals Inc.

[WKN: A1W2RM | ISIN: US00847X1046]

30,100€ 2,03%

Echtzeit-Aktienkurs Agios Pharmaceuticals Inc.

Bid: Ask:

Nachrichten zur Agios Pharmaceuticals Inc. Aktie

» Nachrichtenticker öffnen

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)

…

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -0.58% and 11.76%, respectively, for the quarter ended December 2024. Do…

Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision

…

Agios Pharmaceuticals: A Long Overdue Follow Up

…

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism…

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

…

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…

Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this…

Agios Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

…

‹
1
›